NCT04545541View on ClinicalTrials.gov

Nebulised Heparin in Patients With Severe COVID-19

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

April 30, 2024

Study Completion Date

June 30, 2025

Conditions
Covid19Respiratory Failure
Interventions
DRUG

Nebulised unfractionated heparin (UFH)

Nebulised UFH (25,000 Units in 5 mL) will be administered 6-hourly via an Aerogen Solo vibrating mesh nebuliser while patients receive invasive mechanical ventilation in ICU and for a maximum of 10 days.

Trial Locations (1)

21701

Frederick Health Hospital, Frederick

All Listed Sponsors
lead

Australian National University

OTHER